Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

NCT05412290 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

B Cell Lymphoma
Aggressive Lymphoma
Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma
Follicular Lymphoma Grade 3

Interventions

DRUG: Mosunetuzumab

Sponsor

Washington University School of Medicine

Collaborators

[object Object]